Hemoglobinopathies Clinical Trial
Official title:
A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases
The purpose of this study is to determine a safe dose of BPX-501 gene modified T cells infused after a haplo-identical stem cell transplant to facilitate engraftment and the safety of Rimiducid (AP1903) on day 7 to prevent GVHD.
This is a single arm dose finding study evaluating the safety and efficacy of a BPX 501 infusion (T cells genetically modified with the inducible Caspase 9 suicide gene) of 3x10E6 to 1X10E7 cells/kg followed by a Rimiducid infusion on day 7 after a partially mismatched, related, T cell-depleted hematopoietic cell transplantation (HCT) in patients with non-malignant diseases. The purpose of this clinical trial is to determine the dose of BPX 501 T cell infusion with subsequent planned infusion of Rimiducid which can facilitate engraftment and prevent the occurrence of GVHD. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
| Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Recruiting |
NCT06107400 -
Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
|
Early Phase 1 | |
| Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
| Completed |
NCT00744692 -
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
|
Phase 1 | |
| Recruiting |
NCT05799118 -
Study of the Role of Genetic Modifiers in Hemoglobinopathies
|
||
| Active, not recruiting |
NCT03745287 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT00673608 -
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
|
Phase 4 | |
| Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
| Recruiting |
NCT04853576 -
A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05356195 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
|
Phase 3 | |
| Completed |
NCT03609840 -
Study of Thiotepa and TEPA Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Active, not recruiting |
NCT01850108 -
Non-Myeloablative Conditioning and Bone Marrow Transplantation
|
N/A | |
| Recruiting |
NCT05329649 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
|
Phase 3 | |
| Active, not recruiting |
NCT01966367 -
CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT00153985 -
Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
|
Phase 2 | |
| Recruiting |
NCT03128996 -
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
|
Phase 1/Phase 2 | |
| Completed |
NCT03149289 -
Hepatitis C Virus Infection in Patients With Hemoglobinopathies
|
N/A | |
| Completed |
NCT00000588 -
Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
|
Phase 2 |